Double-Drug attack shows promise for tough head and neck cancers
NCT ID NCT03370276
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tested whether combining two approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. About 95 adults with this type of cancer took part. The goal was to see if the combination was safe and could improve survival and shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.